Motexafin gadolinium

Motexafin gadolinium is being developed under the name XCYTRIN for the enhancement of A -radiation. www.pcyc.com. 

Motexafin gadolinium, 24 56 Motexafin lutetium, 24 56 Moths, sex attractants of, 22 269 Motion... 

Carde, P. et al. (2001) Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases, J. Clin. Oncol. 19, 2074-2083. 

Sessler, J.L. et al. (2001) Probing the reactivity of the radiation sensitizer motexafin gadolinium (Xcytrin) and a series of lanthanide(III) analogues in the presence of both hydroxyl radicals and aqueous electrons, J. Porphyrins Phthalocyanines 5, 593-599. 

Anonymous (2004) Motexafin gadolinium gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120, Drugs in R D 5, 52-57. 

Woodbum, K.W. (2001) Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy, J. Pharm. Exper. Ther. 297, 888-894. 

Magda, D. et al. (2001) Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species, Int. J. Radiat. Oncol. Biol. 51, 1025-1036. 

Sessler, J.L. et al. (2001) Pulse Radiolytic Studies of Metallotexaphyrins in the Presence of Oxygen Relevance of the Equilibrium with Superoxide Anion to the Mechanism of Action of the Radiation Sensitizer Motexafin Gadolinium (Gd-Tex2+, Xcytrin), J. Phys. Chem. B 105, 1452-1457. 

Miller, R. A. et al. (2001) Motexafin gadolinium A redox active drug that enhances die efficacy of bleomycin and doxorubicin, Clin. Cancer Res. 7, 3215-3221. 

Two texaphyrin (aromatic pentadentate ligands) complexes, motexafin gadolinium and lutetium, were extracted fixim plasma and separated on a SS°C C g column (A = 470 nm) using a 59/21/20 water (0.1 M ammonium acetate to pH 4.3 with acetic acid)/acetonitrile/methanol mobile phase. Peaks were well resolved and elution was complete in 20min. Linear ranges from 0.01-30pM and quantitation limits of 0.01 pM gadolinium and 0.1 pM lutetium were reported [925]. 

Updates on many of these projects are presented in other chapters of this monograph. For exan le, motexafin gadolinium (Xcytrin), which was discussed by Richard A. Miller of Pharmacyclics, has now been shown to be of benefit as a potentiator of whole brain radiation therapy for brain metastases in Phase III clinical trials 17). 

Mechanistic Studies of Motexafin Gadolinium (Xcytrin ) A Redox Active Agent That Reacts with Electron-Rich Biological Substrates... 

---